Tumor heterogeneity-based resistance guides personalized cancer medicine

Recent evidence on tumor heterogeneity shapes a new era in achieving personalized cancer medicine. Indeed, despite advances in modern oncology with standardized single biopsy-based approaches, limitations still exist in predicting resistance to therapies and tumor progression. In this editorial, we will summarize the potential clinical benefits and challenges by translating tumor heterogeneity data into clinical oncology.

Click here to view full article.